FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225725306> ?p ?o ?g. }

• W4225725306 endingPage "100036" @default.
• W4225725306 startingPage "100036" @default.
• W4225725306 abstract "Bladder cancer is the tenth most common cancer worldwide. Considering its high prevalence (vulnerability to multiple recurrences and progression despite local therapy), which leads to a substantial health service burden, it becomes necessary to develop new strategies to increase the effectiveness of bladder tumor therapy. Natural compounds with antiproliferative effect on cancer cells could be a good choice for co-adjuvant chemotherapy. Microorganisms are one of the main sources for natural compounds. Pigments extracted from the cold-adapted microorganisms can contribute to the development of a broader range of applications in biotechnology. Violacein is a purple pigment commonly produced by many bacterial strains. We have previously shown that very low concentrations of violacein extracted from Janthinobacterium sp. produced an antiproliferative effect on HeLa cells. With the aim to determine if violacein has an antiproliferative activity on bladder cancer cells, as well as to test if it has synergistic effects on cisplatin treated cells in vitro, T24 and 253J cell lines (derived bladder cancer cells from carcinoma in situ and retroperitoneal metastasis, respectively) were exposed to different concentrations of violacein in the presence or absence of cisplatin. i) Resazurin assay and flow cytometry were performed in two bladder cancer-derived cell lines, namely T24 and 253J, to see if violacein affects cell viability and induce cell death. ii) To find out whether violacein sensitizes bladder cancer cells to cisplatin, the drug interaction among different doses of cisplatin and violacein was analyzed, as well their combination index was determined. iii) The effect of violacein to induce primary genetic damage was determined through the analysis of induced micronuclei frequency and γH2AX foci, as well as performing the comet assay. The half-maximal inhibitory concentration of violacein at 24 h for both cell lines were around 500 nM, and decreased below 400 nM in combination with 10 µM of cisplatin, indicating antiproliferative and sensitizing effects of violacein to cisplatin in both cell lines tested. A clear cell cycle delay, as well as an increase in the percentage of cell death was observed by flow cytometry at 300 nM of violacein, either alone or in combination with cisplatin. On the other hand, the analysis of the micronucleus frequency did not evidence an increase in genetic damage. Moreover, in combined treatments with cisplatin there was a slight decrease on micronucleus induction. Besides, the induction of genetic damage was not observed through comet assay when cells were treated with violacein alone, however, when cells were treated with violacein in the presence of cisplatin (10 µM). The production of genetic damage was diminished in T24 or 253J cells. By the same token, increase in the frequency of γH2AX foci by violacein was not observed at any tested dose in both cell lines. It was shown that violacein has an in vitro antiproliferative effect in bladder cancer cell lines, sensitizing them to cisplatin. Interestingly, at doses tested, violacein did not induce genotoxicity and reduce the genotoxic effect produced by cisplatin." @default.
• W4225725306 created "2022-05-05" @default.
• W4225725306 creator A5030723926 @default.
• W4225725306 creator A5069072097 @default.
• W4225725306 creator A5070056667 @default.
• W4225725306 creator A5076474727 @default.
• W4225725306 date "2022-06-01" @default.
• W4225725306 modified "2023-09-25" @default.
• W4225725306 title "Chemosensitizer Effect of Violacein on Cisplatin-treated Bladder Cancer Cells" @default.
• W4225725306 cites W1569791541 @default.
• W4225725306 cites W1601705983 @default.
• W4225725306 cites W1711618159 @default.
• W4225725306 cites W1852143120 @default.
• W4225725306 cites W1932210666 @default.
• W4225725306 cites W1966834115 @default.
• W4225725306 cites W1987604182 @default.
• W4225725306 cites W2004082126 @default.
• W4225725306 cites W2006480812 @default.
• W4225725306 cites W2009857031 @default.
• W4225725306 cites W2011767881 @default.
• W4225725306 cites W2034175020 @default.
• W4225725306 cites W2042463130 @default.
• W4225725306 cites W2045893119 @default.
• W4225725306 cites W2060286683 @default.
• W4225725306 cites W2112784018 @default.
• W4225725306 cites W2114829464 @default.
• W4225725306 cites W2120197641 @default.
• W4225725306 cites W2126635650 @default.
• W4225725306 cites W2126902508 @default.
• W4225725306 cites W2141037581 @default.
• W4225725306 cites W2167279371 @default.
• W4225725306 cites W2196566976 @default.
• W4225725306 cites W2295302143 @default.
• W4225725306 cites W2414600312 @default.
• W4225725306 cites W2754437817 @default.
• W4225725306 cites W2807936125 @default.
• W4225725306 cites W2903269017 @default.
• W4225725306 cites W2904787830 @default.
• W4225725306 cites W2906823192 @default.
• W4225725306 cites W2909654698 @default.
• W4225725306 cites W2915528638 @default.
• W4225725306 cites W2966483284 @default.
• W4225725306 cites W2968896078 @default.
• W4225725306 cites W2973507237 @default.
• W4225725306 cites W2982555156 @default.
• W4225725306 cites W3031657726 @default.
• W4225725306 cites W3042681680 @default.
• W4225725306 cites W3128646645 @default.
• W4225725306 cites W3204590193 @default.
• W4225725306 doi "https://doi.org/10.1016/j.ccmp.2022.100036" @default.
• W4225725306 hasPublicationYear "2022" @default.
• W4225725306 type Work @default.
• W4225725306 citedByCount "2" @default.
• W4225725306 countsByYear W42257253062023 @default.
• W4225725306 crossrefType "journal-article" @default.
• W4225725306 hasAuthorship W4225725306A5030723926 @default.
• W4225725306 hasAuthorship W4225725306A5069072097 @default.
• W4225725306 hasAuthorship W4225725306A5070056667 @default.
• W4225725306 hasAuthorship W4225725306A5076474727 @default.
• W4225725306 hasBestOaLocation W42257253061 @default.
• W4225725306 hasConcept C109316439 @default.
• W4225725306 hasConcept C121608353 @default.
• W4225725306 hasConcept C126322002 @default.
• W4225725306 hasConcept C1491633281 @default.
• W4225725306 hasConcept C202751555 @default.
• W4225725306 hasConcept C203014093 @default.
• W4225725306 hasConcept C2776375370 @default.
• W4225725306 hasConcept C2776694085 @default.
• W4225725306 hasConcept C2777366897 @default.
• W4225725306 hasConcept C2778239845 @default.
• W4225725306 hasConcept C2780352672 @default.
• W4225725306 hasConcept C502942594 @default.
• W4225725306 hasConcept C53227056 @default.
• W4225725306 hasConcept C55493867 @default.
• W4225725306 hasConcept C71924100 @default.
• W4225725306 hasConcept C86803240 @default.
• W4225725306 hasConcept C96232424 @default.
• W4225725306 hasConcept C98274493 @default.
• W4225725306 hasConceptScore W4225725306C109316439 @default.
• W4225725306 hasConceptScore W4225725306C121608353 @default.
• W4225725306 hasConceptScore W4225725306C126322002 @default.
• W4225725306 hasConceptScore W4225725306C1491633281 @default.
• W4225725306 hasConceptScore W4225725306C202751555 @default.
• W4225725306 hasConceptScore W4225725306C203014093 @default.
• W4225725306 hasConceptScore W4225725306C2776375370 @default.
• W4225725306 hasConceptScore W4225725306C2776694085 @default.
• W4225725306 hasConceptScore W4225725306C2777366897 @default.
• W4225725306 hasConceptScore W4225725306C2778239845 @default.
• W4225725306 hasConceptScore W4225725306C2780352672 @default.
• W4225725306 hasConceptScore W4225725306C502942594 @default.
• W4225725306 hasConceptScore W4225725306C53227056 @default.
• W4225725306 hasConceptScore W4225725306C55493867 @default.
• W4225725306 hasConceptScore W4225725306C71924100 @default.
• W4225725306 hasConceptScore W4225725306C86803240 @default.
• W4225725306 hasConceptScore W4225725306C96232424 @default.
• W4225725306 hasConceptScore W4225725306C98274493 @default.
• W4225725306 hasIssue "2" @default.
• W4225725306 hasLocation W42257253061 @default.

• next